Reuters - Video

Edition: US | UK | IN | CN | JP

video Business

Biogen shares tank on scrapping Alzheimer trials

Thursday, March 21, 2019 - 00:58

Biogen and its partner, Eisai, are scrapping two late-stage trials for a potential treatment for Alzheimer's. As Fred Katayama reports, Biogen shares dropped 27 percent.

▲ Hide Transcript

View Transcript

Biogen and its partner, Eisai, are scrapping two late-stage trials for a potential treatment for Alzheimer's. As Fred Katayama reports, Biogen shares dropped 27 percent.

Press CTRL+C (Windows), CMD+C (Mac), or long-press the URL below on your mobile device to copy the code

Biogen shares tank on scrapping Alzheimer trials

Thursday, March 21, 2019 - 00:58